A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial

This article has no abstract
Epistemonikos ID: 75000595c983c1642f0a203a1fb1c4aff1bcc82c
First added on: Feb 12, 2025